TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase

被引:11
|
作者
Chandhasin, Chandtip [1 ]
Dang, Van [1 ]
Perabo, Frank [1 ]
Del Rosario, Joselyn [2 ]
Chen, Young K. [2 ]
Filvaroff, Ellen [2 ]
Stafford, Jeffrey A. [3 ]
Clarke, Michael [4 ]
机构
[1] Tachyon Therapeut Inc, 1160 Battery St East Suite 100, San Francisco, CA 94111 USA
[2] Bristol Myers Squibbm, New York, NY USA
[3] 858 Therapeut, San Diego, CA USA
[4] Stanford Univ, Stanford, CA USA
关键词
epigenetic; histone lysine demethylase; KDM4; TACH101; EMBRYONIC STEM; CELL-PROLIFERATION; ANDROGEN RECEPTOR; SELF-RENEWAL; JMJD2B; EXPRESSION; GASC1; GENE; HETEROCHROMATIN; METHYLATION;
D O I
10.1097/CAD.0000000000001514
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histone lysine demethylase 4 (KDM4) is an epigenetic regulator that facilitates the transition between transcriptionally silent and active chromatin states by catalyzing the removal of methyl groups on histones H3K9, H3K36, and H1.4K26. KDM4 overamplification or dysregulation has been reported in various cancers and has been shown to drive key processes linked to tumorigenesis, such as replicative immortality, evasion of apoptosis, metastasis, DNA repair deficiency, and genomic instability. KDM4 also plays a role in epigenetic regulation of cancer stem cell renewal and has been linked to more aggressive disease and poorer clinical outcomes. The KDM4 family is composed of four main isoforms (KDM4A-D) that demonstrate functional redundancy and cross-activity; thus, selective inhibition of one isoform appears to be ineffective and pan-inhibition targeting multiple KDM4 isoforms is required. Here, we describe TACH101, a novel, small-molecule pan-inhibitor of KDM4 that selectively targets KDM4A-D with no effect on other KDM families. TACH101 demonstrated potent antiproliferative activity in cancer cell lines and organoid models derived from various histologies, including colorectal, esophageal, gastric, breast, pancreatic, and hematological malignancies. In vivo, potent inhibition of KDM4 led to efficient tumor growth inhibition and regression in several xenograft models. A reduction in the population of tumor-initiating cells was observed following TACH101 treatment. Overall, these observations demonstrate the broad applicability of TACH101 as a potential anticancer agent and support its advancement into clinical trials.
引用
收藏
页码:1122 / 1131
页数:10
相关论文
共 50 条
  • [1] TACH101, a first-in-class pan-inhibitor of KDM4 for treatment of gastrointestinal cancers
    Perabo, Frank
    Chandhasin, Chandtip
    Yoo, Sanghee
    Dang, Van
    Del Rosario, Joselyn
    Chen, Young K.
    Stafford, Jeffrey
    Quake, Stephen
    Clarke, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] TACH101, a first-in-class pan inhibitor of KDM4 histone lysine demethylases.
    Yoo, Sanghee
    Chandhasin, Chandtip
    Del Rosario, Joselyn R.
    Chen, Young K.
    Stafford, Jeff
    Quake, Stephen
    Perabo, Frank
    Clarke, Michael F.
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Identification of pharmacodynamic and sensitivity biomarkers for TACH101, a pan-inhibitor of KDM4 histone lysine demethylase
    Perabo, Frank
    Yoo, Sanghee
    Chandhasin, Chandtip
    Del Rosario, Joselyn
    Chen, Young K.
    Filvaroff, Ellen
    Stafford, Jeffrey A.
    Quake, Stephen
    Clarke, Michael F.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [4] Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4.
    Chandhasin, Chandtip
    Yoo, Sanghee
    Del Rosario, Joselyn
    Chen, Young K.
    Stafford, Jeffrey
    Perabo, Frank
    Clarke, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Inhibition of cancer stem cells with TACH101, a first-in-class inhibitor of KDM4 histone lysine demethylase.
    Perabo, Frank
    Chandhasin, Chandtip
    Dang, Van
    Del Rosario, Joselyn
    Chen, Young K.
    Filvaroff, Ellen
    Stafford, Jeffrey
    Quake, Stephen
    Clarke, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] TACH101, a first-in-class inhibitor of KDM4 histone lysine demethylase for the treatment of diffuse large B-cell lymphoma
    Perabo, Frank
    Chandhasin, Chandtip
    Yoo, Sanghee
    Del Rosario, Joselyn
    Chen, Young K.
    Filvaroff, Ellen
    Stafford, Jeffrey A.
    Quake, Stephen
    Clarke, Michael F.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Pharmacologic characterization of TACH101, a first-in-class KDM4 inhibitor for development as a cancer therapeutic.
    Yoo, Sanghee
    Chandhasin, Chandtip
    Del Rosario, Joselyn
    Chen, Young K.
    Stafford, Jeffrey
    Perabo, Frank
    Clarke, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors
    Tsimberidou, Apostolia
    Vandross, Andrae L.
    Sommerhalder, David
    Joseph, Charmaine
    Chandhasin, Chandtip
    Perabo, Frank
    Clarke, Michael F.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [9] Histone methylation changes of H3K9 and H3K36 in PBMCs as pharmacodynamic biomarkers for Zavondemstat (TACH101), a pan-inhibitor of KDM4 histone lysine demethylase
    Chandhasin, C.
    Perabo, F.
    Dai, Y.
    DiMascio, L.
    Mehta, R. K.
    Hassan, M. K.
    Nyati, M. K.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S95 - S95
  • [10] Discovery of a first-in-class PROTAC degrader of histone lysine demethylase KDM4
    Rao, Danni
    Wang, Yiting
    Yang, Xiaolong
    Chen, Zhiwen
    Wu, Feifei
    Ren, Ran
    Sun, Yaoliang
    Lai, Yuanhui
    Peng, Lijie
    Yu, Lei
    Zhang, Zhang
    Xu, Shilin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 288